Pharmaniaga Berhad (KLSE:PHARMA)
Malaysia · Delayed Price · Currency is MYR 1.160
-0.010 (-0.85%)
At close: Aug 28, 2026
Pharmaniaga Berhad Ratios and Metrics
Market cap in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,521 | 1,869 | 512 | 555 | 714 | 969 | |
Market Cap Growth | 32.57% | 265.25% | -7.79% | -22.28% | -26.35% | -25.92% |
Enterprise Value | 2,174 | 2,541 | 1,709 | 1,690 | 1,800 | 1,749 |
Last Close Price | 1.16 | 1.41 | 1.05 | 1.13 | 1.61 | 1.99 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.36 | 38.52 | 3.88 | - | - | 5.63 |
Forward PE | 6.26 | 20.71 | 10.60 | 24.06 | 11.24 | 11.53 |
PS Ratio | 0.37 | 0.48 | 0.14 | 0.16 | 0.21 | 0.20 |
PB Ratio | 3.15 | 4.07 | -3.51 | -2.02 | -2.05 | 2.06 |
P/TBV Ratio | 4.12 | 5.58 | - | - | - | 3.95 |
P/FCF Ratio | - | - | 44.46 | - | - | - |
P/OCF Ratio | - | - | 11.99 | 11.82 | - | - |
PEG Ratio | - | 1.14 | 1.14 | 1.14 | 1.14 | 0.85 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.52 | 0.65 | 0.45 | 0.50 | 0.52 | 0.36 |
EV/EBITDA Ratio | 13.76 | 16.47 | 5.92 | 229.97 | 32.36 | 5.22 |
EV/EBIT Ratio | 17.18 | 19.60 | 6.55 | - | 64.27 | 5.69 |
EV/FCF Ratio | - | - | 148.48 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.62 | 1.79 | -8.17 | -4.35 | -3.35 | 1.82 |
Debt / EBITDA Ratio | 4.94 | 4.97 | 3.98 | 65.02 | 18.83 | 2.53 |
Debt / FCF Ratio | - | - | 103.57 | - | - | - |
Net Debt / Equity Ratio | 1.30 | 1.18 | -7.23 | -3.92 | -3.19 | 1.70 |
Net Debt / EBITDA Ratio | 4.26 | 3.51 | 3.66 | 146.13 | 19.98 | 2.38 |
Net Debt / FCF Ratio | -4.32 | -11.42 | 91.75 | -288.57 | -5.51 | -8.46 |
Asset Turnover | 1.80 | 1.85 | 1.92 | 1.81 | 1.70 | 2.51 |
Inventory Turnover | 5.48 | 5.24 | 5.39 | 4.60 | 3.09 | 4.52 |
Quick Ratio | 0.55 | 0.43 | 0.29 | 0.24 | 0.19 | 0.22 |
Current Ratio | 1.01 | 0.91 | 0.62 | 0.55 | 0.58 | 1.11 |
Return on Equity (ROE) | 33.70% | 32.36% | - | - | -1027.82% | 41.73% |
Return on Assets (ROA) | 3.41% | 3.82% | 8.35% | -0.68% | 0.85% | 10.01% |
Return on Invested Capital (ROIC) | 8.28% | 16.90% | - | - | 5.34% | 16.94% |
Return on Capital Employed (ROCE) | 14.90% | 20.40% | 665.10% | 23.30% | -12.70% | 38.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.87% | 2.60% | 25.77% | -14.45% | -88.23% | 17.76% |
FCF Yield | -9.58% | -2.54% | 2.25% | -0.67% | -28.24% | -9.74% |
Dividend Yield | 1.45% | - | - | - | 5.92% | 23.38% |
Payout Ratio | - | - | - | - | - | 34.24% |
Buyback Yield / Dilution | -328.22% | -150.74% | -5.38% | -4.40% | -0.05% | -0.04% |
Total Shareholder Return | -326.76% | -150.74% | -5.38% | -4.40% | 5.87% | 23.34% |